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Background: The benefits of indicated primary preven-
tion among individuals at Clinical High Risk for Psychosis 
(CHR-P) are limited by the difficulty in detecting these 
individuals. To overcome this problem, a transdiagnostic, 
clinically based, individualized risk calculator has recently 
been developed and subjected to a first external validation 
in 2 different catchment areas of the South London and 
Maudsley (SLaM) NHS Trust. Methods: Second external 
validation of real world, real-time electronic clinical regis-
ter-based cohort study. All individuals who received a first 
ICD-10 index diagnosis of nonorganic and nonpsychotic 
mental disorder within the Camden and Islington (C&I) 
NHS Trust between 2009 and 2016 were included. The 
model previously validated included age, gender, ethnic-
ity, age by gender, and ICD-10 index diagnosis to predict 
the development of any ICD-10 nonorganic psychosis. The 
model’s performance was measured using Harrell’s C-index. 
Results: This study included a total of 13 702 patients with 
an average age of 40 (range 16–99), 52% were female, and 
most were of white ethnicity (64%). There were no CHR-P 
or child/adolescent services in the C&I Trust. The C&I and 
SLaM Trust samples also differed significantly in terms 
of age, gender, ethnicity, and distribution of index diagno-
sis. Despite these significant differences, the original model 
retained an acceptable predictive performance (Harrell’s 
C of 0.73), which is comparable to that of CHR-P tools 
currently recommended for clinical use. Conclusions: This 
risk calculator may pragmatically support an improved 
transdiagnostic detection of at-risk individuals and psycho-
sis prediction even in NHS Trusts in the United Kingdom 
where CHR-P services are not provided.
Key words:  psychosis/schizophrenia/transdiagnostic, 
risk calculator/validation
Introduction
Individuals at Clinical High Risk for Psychosis (CHR-
P1) present with subtle symptoms and overall functional 
impairment.2 In the wake of these problems, they seek help 
at specialized CHR-P clinics.3 CHR-P individuals have 20% 
probability of developing incident psychotic disorders (but 
not other nonpsychotic disorders4,5) over a relatively short 
period of 2 years.6 Primary indicated prevention in CHR-P 
individuals has the unique potential to alter the course of 
psychosis7 and reduce the duration of untreated psychosis,8,9 
while secondary prevention in CHR-P who will develop the 
disorder can ameliorate the severity of the first episode.10
Currently, these benefits are offered only to those 
CHR-P individuals who are detected by existing recruit-
ment strategies, which rely on: (1) outreach campaigns 
and (2) referrals made on suspicion of psychosis risk 
(figure 1). These strategies are highly inefficient.12 A recent 
study estimated that of the 1001 first-episode cases in sec-
ondary mental health care within the South London and 
Maudsley (SLaM) NHS Trust, only 52 (5%) were referred 
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to, and therefore detected by, the local CHR-P service 
before the manifestation of their illness13 (figure  1). The 
negligible number of cases detected in real-life settings 
by the CHR-P paradigm is highly problematic because it 
severely hinders our ability to change the course of psy-
chosis.12 Furthermore, there is a window of missed oppor-
tunity for the prevention of psychosis because all of these 
individuals were already under the care of mental health 
services.13 Leading experts have capitalized on these cave-
ats to question the overall clinical utility of the CHR-P 
paradigm.14 To overcome these problems, a transdiag-
nostic, clinically based, individualized risk calculator has 
recently been developed in the Lambeth and Southwark 
boroughs of SLaM.13 The calculator employs electronic 
health data and therefore can be applied at scale to detect 
all individuals at risk of developing psychosis in secondary 
mental health care (see figure 2 for a simple presentation 
of this calculator). The model was developed following 
state-of-the-art guidelines which recommend preselecting 
predictors on the basis of a priori knowledge.15 Predictors 
were also limited in number to ensure that there was an 
adequate event per variable ratio (which is recommended 
to develop robust models in the case of relatively infre-
quent outcomes16) on the basis of an established a priori 
empirical link to psychosis risk: age,17 gender,17 ethnicity,17 
and age by gender interaction.17 The ICD-10 nonpsychotic 
diagnoses were selected on the basis of evidence indicating 
that psychosis may emerge from several diagnostic spec-
tra.18 The transdiagnostic properties of this tool mean that 
it can be used in a pragmatic fashion, not merely in CHR-P 
samples, but also in any patient receiving a first ICD-10 
index diagnosis of any nonpsychotic mental disorder.13 This 
calculator has already demonstrated adequate prognostic 
performance in the first external validation in the SLaM 
boroughs of Lewisham and Croydon (Harrell’s C = 0.79, 
for full details see Fusar-Poli et al13). However, to date, the 
extent to which the calculator can be “transported” into 
other NHS Trusts—that may be characterized by differ-
ent service configurations or patient sociodemographic 
and clinical characteristics—remains unknown. External 
validation studies are essential to evaluate the generaliza-
bility of predictive risk models and to assess whether they 
should be implemented in clinical practice.19
The current study investigates the external validity of 
the original transdiagnostic, clinically based, individual-
ized risk calculator in an independent data set represen-
tative of the Camden and Islington (C&I) NHS Trust.
Materials and Methods
Setting: Camden and Islington NHS Trust and Clinical 
Record Interactive Search
C&I NHS Trust is a large mental health care provider that 
serves a geographic catchment area of 2 inner-city London 
Fig. 1. Current detection strategies for individuals at risk of psychosis in secondary mental health care in South London, UK. The local 
early detection service (OASIS3), which is embedded in the South London and Maudsley (SLaM) NHS Trust, runs an ongoing outreach 
to promote referrals on suspicion of psychosis risk.11 This strategy is highly inefficient and misses 95% of patients who are at risk and 
who will develop a first episode of psychosis over the ensuing 4 years.12
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boroughs, and nearly 470 000 residents. It provides men-
tal health and substance misuse services to adults living in 
Camden and Islington. In addition, the Trust provides sub-
stance misuse services to Westminster, as well as substance 
misuse and psychological therapies services to the residents 
of Kingston. It has 2 inpatient facilities, at Highgate Mental 
Health Centre and St Pancras Hospital, as well as commu-
nity-based services throughout the London boroughs of 
Camden and Islington. The services accommodate adults 
of working age, adults with learning difficulties, and older 
people across the community or in inpatient settings. The 
Trust does not provide CHR-P services or child and ado-
lescent services, with the exception of the Camden Early 
Intervention Service, which accepts referrals over the age of 
14. The C&I Trust uses the same Clinical Record Interactive 
Search (CRIS) system as used in SLaM.20 The CRIS C&I 
database comprised complete but anonymized informa-
tion from over 116 000 mental health patients.21 C&I CRIS 
received ethical approval from the NRES Committee East 
of England—Cambridge Central (14/EE/0177).
Statistical Analysis
This clinical register-based cohort study was conducted 
according to the REporting of studies Conducted 
using Observational Routinely collected health Data 
(RECORD) Statement22 (see checklist reported in 
supplementary eTable 1).
Baseline clinical and sociodemographic characteristics 
of the sample (including missing data) were described by 
means and SDs for continuous variables, and absolute and 
relative frequencies for categorical variables. The overall 
cumulative risk of psychosis onset (see below) in the C&I 
NHS Trust was described with the Kaplan–Meier failure 
function (1—survival)23 and Greenwood 95% CIs.24
Model Specifications. We used the original transdiagnos-
tic clinically based individualized risk calculator, which 
was developed through CRIS in the SLaM boroughs of 
Lambeth and Southwark, and validated in the SLaM 
boroughs of Croydon and Lewisham.13 In summary, a 
Cox model was used to predict as primary outcome of 
interest the hazard ratio (HR) of developing any psy-
chotic disorder over time (see supplementary eMethods 1 
for definition). The predictors included age (at the time of 
the index diagnosis), gender, age by gender, self-assigned 
ethnicity, and index diagnosis. Self-assigned ethnicity and 
index diagnoses were operationalized as indicated in sup-
plementary eTables  2 and 3. These definitions matched 
the operationalizations of the original model.13 The fol-
low-up commenced 3 months after the date of the index 
diagnosis within the C&I NHS Trust and was censored 
on October 30, 2016, in line with the previous analysis.13 
As for the original report,13 this lag period was chosen to 
allow patients sufficient time after their index diagnosis 
to meet the ICD-10 duration criterion for brief  psychotic 
episodes—that are usually included under the CHR-P 
designation25—and to exclude individuals who were 
underreporting psychotic symptoms at baseline (false 
transition to psychosis).26
Second External Model Validation. Model valida-
tion followed the guidelines of Royston and Altman,27 
Steyerberg et  al,28 and the Transparent Reporting of a 
Fig. 2. Potential clinical use of the individualized, clinically based, transdiagnostic risk calculator in secondary mental health care. For 
any new patient accessing the local NHS Trust (South London and Maudsley, UK) clinicians will enter the predictors on the electronic 
case register, as part of their clinical routine. The calculator, embedded in the electronic system, would then use the predictors to estimate 
the individual risk of developing psychosis over time. This information would then be shared with clinicians through automated alerts, 
inform their decision making and promote appropriate referrals to the local early detection clinic (OASIS3).
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multivariable prediction model for Individual Prognosis 
Or Diagnosis (TRIPOD).29 An independent researcher 
(N.W.) who had access to the original data performed 
the analyses under the supervision of a senior researcher 
(P.F.P.) who also led the development and validation of 
the original risk calculator. To ensure proper external val-
idation, P.F.P. limited his contribution to the sharing of 
the STATA script (supplementary eMethods 2). P.F.P. did 
not have any direct access to the original database and 
did not run the analyses.
To interpret the performance of a risk model in the con-
text of external validation, it is essential to first quantify 
the degree of relatedness between development and val-
idation samples.19 External validity only assesses model 
transportability if  validation samples have a different case 
mix. Thus, we investigated the extent to which the SLaM 
and C&I data sets comprised patients with sets of prognos-
tically relevant predictors in common, comparable time-
to-event outcomes with roughly similar follow-up times, 
and the same clinical condition observed in similar set-
tings.30 As a first step, we visually compared the 2 Kaplan–
Meier failure functions. If the curves vary noticeably or 
if  there are differences in their shapes, systematic differ-
ences within the study populations may be indicated.30 We 
also reported the spread (SD) and mean of the prognostic 
index of the model in the 2 NHS Trusts. An increased (or 
decreased) variability of the prognostic index would indi-
cate more (or less) heterogeneity of case mix between the 
2 NHS Trusts, and therefore, of their overarching target 
populations.19 Differences in the mean prognostic index 
indicate differences in overall (predicted) outcome fre-
quency, reflecting case-mix severity between the 2 NHS 
Trusts (and revealing the model’s calibration-in-the-large 
in the C&I database).19 As a second step, we compared the 
distributions of predictors between the SLaM and C&I 
datasets.30 Here, substantial differences may also indicate 
important differences in the study populations.30
We then conducted the formal external validation.30 
Accordingly, the regression coefficients estimated in the 
SLaM NHS Trust13 were applied to each case in the exter-
nal C&I NHS Trust, to generate the prognostic index in 
the C&I NHS Trust. Since we were interested in discrim-
ination, the primary outcome measure for model perfor-
mance (accurate predictions discriminate between those 
with and those without the outcome28) was Harrell’s 
C-index.27 Harrell’s C is a recommended measure for 
external validation of Cox models according to estab-
lished guidelines.27 Harrell’s C is the probability that for a 
random pair of “case” and “control,” the predicted risk 
of an event is higher for the “case”: values of 0.9–1.0 are 
considered outstanding, 0.8–0.9 excellent and 0.7–0.8 
acceptable.31 In addition, we estimated the overall model 
performance28 using the Brier score (the average mean 
squared difference between predicted probabilities and 
actual outcomes, which also captures calibration and dis-
crimination aspects28). Calibration (the agreement between 
observed outcomes and predictions28) was assessed using 
the regression slope of the prognostic index.27,28 Finally, 
since recent studies indicate that it is possible to achieve an 
unbiased and precise estimation of performance measures 
with a minimum of 100 events in the external validation 
data set,32 we also reported the number of events that were 
observed in the C&I NHS database.
Model Updating. As a further exploratory step, we 
updated the model using the regression slope on prog-
nostic index as shrinkage factor for recalibration, in line 
with the Royston et al guidelines.30
All analyses were conducted in STATA 11 and signifi-
cance was set to P <.05.
Results
C&I NHS Trust Sample Characteristics
A total of 13 702 patients accessing C&I NHS Trust 
between January 1, 2009 and October 30, 2016 received 
an ICD-10 index diagnosis other than psychosis. Patients 
accessing the C&I NHS Trust and included in the current 
study had an average age of 40 years (range 16–99, only 
41 individuals were aged 16–17), 52% were female, and 
most were of white ethnicity (64%). The most frequent 
index diagnosis was nonbipolar mood disorders (28%). 
Missing data related mostly to ethnicity (10.8%, table 1).
Differences Between the C&I and SLaM NHS Trusts
Sociodemographic Differences. As noted above, the C&I 
NHS Trust neither included CHR-P services nor child and 
adolescent services. As a result, the average age in the C&I 
NHS Trust was 6.5 years higher than in SLaM, whereas 
the proportion of developmental or childhood/adolescence 
onset disorders was lower in C&I than in SLaM (table 1, 
post hoc P < .001). There were also fewer males and con-
siderably fewer patients of black ethnicity in the C&I Trust 
(8% vs 20%, post hoc P < .001). Compared to SLaM, sub-
stance abuse disorders, nonbipolar mood disorders, mood 
disorders, and personality disorders were more prevalent in 
the C&I NHS Trust, whereas anxiety disorders were rela-
tively less frequent (post hoc P < .001). Finally, physiolog-
ical syndromes were found to be more prevalent in SLaM 
as compared with the C&I NHS Trust (post hoc P < .001).
Cumulative Risk of Psychosis in C&I NHS Trust Compared 
With the SLaM NHS Trust. The average follow-up time 
was 37.17 months (SD = 22.25). The average time to tran-
sition to psychosis was 20.08 months (SD = 18.14). The 
cumulative risk of psychosis in the C&I NHS Trust is 
plotted in figure 3, with the last transition being observed 
at 2466 days.  The 6-year point estimate in SLaM was 
3.02 (95% CI = 2.88–3.15), with the last transition being 
observed at 2099 days (see eFigure 1 in [ref11]). Mean val-
ues of the prognostic index within the C&I and SLaM 
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Trusts were −1.06 and −1.32, respectively (post hoc P < 
.001). SD of the prognostic index in the C&I and SLaM 
Trusts were 0.84 and 0.89, respectively (post hoc P < .001).
Second External Validation of the Original Model in 
the C&I NHS Trust
The primary performance measure in the C&I NHS Trust 
was acceptable, with a Harrell’s C of 0.73. The model 
was not well calibrated and was under-fitting the data, 
with a regression slope of 0.750, 95% CI = 0.687–0.813 
(P < .001). The Brier score at 6-year was 0.038 (6-year 
Brier score in SLaM = 0.027). The full specifications of 
the model are reported in supplementary eTable 4.
Model Updating
Model updating improved calibration (regression 
slope = 1), but there was no substantial improvement of 
model performance, which remained acceptable, with a 
significant Harrell’s C of 0.73.
Discussion
This is one of the few predictive modeling replica-
tion studies in early psychosis. We showed evidence for 
large-scale clinical transportability of the transdiagnostic, 
clinically based, individualized risk calculator to another 
NHS Trust in the United Kingdom. The vast majority 
of predictors were available in the secondary NHS Trust 
and were collected as part of standard clinical practice. 
Compared with the NHS Trust wherein this model was 
developed, the secondary NHS Trust was characterized 
by significant differences in service configuration (there 
were no child/adolescent or CHR-P services) and in 
sociodemographic characteristics. In the new NHS Trust, 
the risk calculator was able to retain acceptable prognos-
tic performance to a level comparable with that of cur-
rent CHR-P psychometric interviews.
The key finding of this study is that the overall prognos-
tic accuracy of the transdiagnostic clinically based risk 
calculator was externally replicated, resulting in accepta-
ble performance statistics. Notably, the level of prognos-
tic accuracy (Harrell’s C = 0.73) was comparable to that 
of CHR-P psychometric instruments currently used in 
clinical practice. In fact, our last prognostic meta-analysis 
showed that the Comprehensive Assessment of At Risk 
Mental States—which is the NICE-recommended instru-
ment for detecting individuals at risk of psychosis—is 
characterized by similar adequate prognostic accuracy 
(area under the curve at 2 years = 0.79).33 These findings 
Table 1. Sociodemographic Characteristics of the Camden and Islington (C&I) NHS Trust Compared With the South London and 
Maudsley (SLaM) NHS Trust, UK
Variable
C&I (n =13 702) SLaM (n = 33 820)a C&I Vs SLaM
Mean (SD) Mean (SD) P
Age, y 40.91 (15.14) 34.4 (18.92) <.001
No. (%) No. (%)
Sex <.001
 Male 6582 (48.04) 17 303 (51.16)
 Female 7118 (51.95) 16 507 (48.81)
 Missing 2 (0.01) 10 (0.03)
Ethnicity <.001
 Black 1189 (8.68) 6879 (20.34)
 White 8804 (64.25) 18 627 (55.08)
 Asian 762 (5.56) 1129 (3.34)
 Mixed 469 (3.42) 1306 (3.86)
 Other 998 (7.28) 3466 (10.25)
 Missing 1480 (10.80) 2413 (7.13)
Index diagnosis <.001
 CHR-P — 314 (0.93)
 Acute and transient psychotic disorders 427 (2.74) 553 (1.64)
 Substance use disorders 3428 (25.04) 7149 (21.14)
 Bipolar mood disorders 936 (7.05) 950 (2.81)
 Nonbipolar mood disorders 3694 (27.70) 6302 (18.63)
 Anxiety disorders 3122 (22.50) 8235 (24.35)
 Personality disorders 1468 (10.45) 1286 (3.80)
 Developmental disorders 111 (0.80) 1412 (4.18)
 Childhood/adolescence onset disorders 295 (2.15) 4200 (12.42)
 Physiological syndromes 170 (1.25) 2555 (7.55)
 Mental retardation 51 (0.34) 864 (2.55)
Note: Clinical High Risk State for psychosis (CHR-P) is defined on the basis of the At Risk Mental State criteria. The index diagnosis 
was formulated at baseline (time of the first contact with the NHS Trust).
aDerivation database: Lambeth and Southwark boroughs.
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confirm the clinical utility of our transdiagnostic calcu-
lator, which has been estimated in our previous publica-
tion13 through rigorous decision curve analyses.34 Our risk 
calculator represents the only available pragmatic way to 
improve the detection of individuals at risk of psychosis 
in secondary mental health care.12 Systematically screen-
ing all individuals accessing NHS Trusts with widespread 
use of CHR-P tools is theoretically viable but logistically 
untenable and financially unsustainable. Implementing 
intensive outreach campaigns to promote referrals on 
clinicians’ suspicion of psychosis risk is highly inefficient 
and we have already demonstrated this issue at meta-
analytical level.11 Intensive outreach campaigns lead to 
diluted risk enrichment35 and to negligible positive pre-
dictive values in those meeting CHR-P criteria.11,36–38 This 
second replication is therefore clinically important; as is 
the case in biomedical science more broadly,39 prognostic 
modeling in early psychosis suffers from a serious replica-
tion crisis,40 to the point that replication becomes equally 
as—or even more—important than discovery.41 A recent 
systematic review and meta-analysis of clinical prediction 
models for predicting the onset of psychosis in CHR-P 
samples uncovered 91 studies, none of which performed 
a true external validation of an existing model.42 Upon 
completion of this meta-analysis, another risk calcula-
tor was developed and validated externally,43,44 although 
its applicability is limited to individuals already meet-
ing CHR-P criteria; it cannot, therefore, be utilized to 
boost the detection of at-risk individuals. In general, 
lack of replication is the primary barrier impeding the 
translation of research promises into real-life biomedical 
applications.41 In predictive modeling, this is often due 
to small samples,45 stepwise selection of variables based 
on significance threshold46 and the scarcity of events to 
be predicted.32,42 Our model successfully bypasses these 
caveats because it has been developed on robust a priori 
meta-analytical clinical knowledge, and validated in very 
large data sets (≈30 000 patients) that encompassed many 
(400–1000) events.
Furthermore, this confirmatory result provides prag-
matic support for the potential clinical transportabil-
ity19 of our calculator into other NHS Trusts, at least 
within the United Kingdom. Demonstrating clinical 
validity requires evaluation of the predictive value in 
real world populations39 such as those encompassed by 
our real world, real-time electronic clinical registers. The 
significant (beyond chance) and acceptable prognostic 
performance is even more convincing in the context of 
the substantial differences found between the C&I and 
SLaM NHS Trusts. For one, the sociodemographic char-
acteristics of the patients were dissimilar across Trusts, 
with SLaM being characterized by greater proportions 
of younger individuals and black ethnicity. More impor-
tantly, the C&I NHS Trust lacked child/adolescent mental 
health services as well as CHR-P services. These differ-
ences likely impacted the proportions of different ICD-10 
index diagnoses across the 2 Trusts. In fact, within the 
C&I NHS Trust, greater proportions of substance abuse 
disorders, nonbipolar mood disorders, mood disorders, 
and personality disorders were observed. The mean 
and SD of the prognostic index across the 2 Trusts con-
firmed some degree of case mix, with higher predicted 
risks and less spread in the C&I Trust. Given such pro-
found differences, it was expected that the risk calculator 
could not be easily transported to the local scenario, and 
thus a lower performance than that observed in the first 
external validation (Harrell’s C  =  0.79)13 was expected. 
From a statistical point of view, the acceptable degree 
of difference between the development and external val-
idation populations is a matter of debate.30 Successful 
replication is particularly relevant for recent national 
clinical guidelines and policies. NHS England and the 
Department of Health recently published the Access 
and Waiting Time Standard for Early Intervention and 
its NICE guidance.47 The guidance requires CHR-P indi-
viduals to be assessed and treated rapidly, and with evi-
dence-based interventions.47 The NICE guidance in this 
area is not evidence-based and by making highly ineffi-
cient detection strategies a national priority, has set itself  
to failure. Not surprisingly, the NICE guidance is already 
introducing operational issues and concerns relating to 
unclear referral pathways and inefficient use of clinical 
resources.48 The efficient detection of at-risk cases marks 
the first step toward successful risk estimation tools for 
Fig. 3. Cumulative incidence (Kaplan–Meier failure function) 
for risk of development of psychotic disorders in the Camden 
and Islington NHS Trust, UK. There were a total of 490 events 
(transition to psychosis). There were 212 events in the first 
365 days, 123 events in the interval 365–730 days, 63 events in the 
interval 730–1095 days, 44 events in the interval 1095–1460 days, 
28 events in the interval 1460–1825 days, 14 events in the interval 
1825–2190 days, 6 events the interval 2190–2555 days, and no 
events in the interval 2555–2851 (end of follow-up). The last 
transition to psychosis was observed at 2466 days, when 13 212 
individuals were still at risk. The point estimates for cumulative 
incidence of psychosis were at: 1 year, 1.61; at 2 year, 2.76; 
3 year, 3.53; 4 year, 4.36; 5 year, 5.19; and 6 year 5.88 (95% CI: 
5.27–6.57).
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clinical practice.49 Our calculator can potentially fill such 
a translational gap, offering a pragmatic approach for the 
successful implementation of the NICE standard. This 
is particularly relevant for the majority of the UK-based 
NHS Trusts that lack established CHR-P services. Since 
the set-up of CHR-P services is challenging from both 
logistical and economic perspectives,3,50 we expect our 
calculator to play a pivotal role by optimizing the recruit-
ment and referral strategies of available service configu-
rations (see below).
The full implementation of this calculator in the wider 
clinical practice of the NHS clearly requires additional 
confirmatory evidence. The next steps would involve rep-
lication in further NHS Trusts in the United Kingdom 
and a prospective feasibility study. Our research team 
is currently conducting these studies. Upon completion 
of this research, we will seek to replicate our calculator 
outside the United Kingdom and will then conduct a 
definitive large-scale effectiveness trial to demonstrate its 
ultimate clinical utility in the real world. Four pragmatic 
aspects of our calculator may facilitate future research 
and its broad clinical use.19 First, the risk calculator is 
simple and only requires basic sociodemographic and 
clinical predictors. Indeed, missing data in the C&I NHS 
Trust were relatively rare,13 indicating that the calculator 
can possibly be used to test large numbers of cases. This 
is a key requisite to boost the detection power across the 
entire secondary mental health care sector. Our calculator 
was conceived and developed within an evidence-based 
pragmatic psychiatry approach.51 In a similar fashion, the 
best known, and probably the most widely used risk esti-
mation tool used in medicine globally, is the Framingham 
pragmatic clinical prediction model. It includes simple 
variables such as sex, age, total and high-density lipopro-
tein (HDL) cholesterol, systolic blood pressure, smoking 
status, diabetes, and hypertensive treatment.49 Second, the 
risk calculator is cheap and does not involve costly proc-
essing, complex techniques, or other accompanying infra-
structures. Rather, it increases the value of public money 
invested in training NHS clinicians, because it capitalizes 
on the time and psychopathological expertise already 
used by clinicians to formulate the index diagnoses. Risk 
estimation systems are of little value unless clinicians 
use them in day-to-day practice.49 Third, implementa-
tion of the risk calculator can leverage on e-Health apps 
and translational informatics, such as the electronic case 
registers of the National Institute for Health Research 
Biomedical Research Centres (NIHR-BRC), which have 
a presence not only in south London (SLaM), but also 
in other sites such as the C&I, Oxford, Cambridge, and 
Newcastle Upon Tyne NHS Trusts. In these sites, the risk 
calculator could be easily automatized, minimizing cod-
ing problems.49 At the same time, NHS Trusts that do not 
have an NIHR-BRC electronic case register could still 
use the online version, which has been made freely availa-
ble.13 Fourth, the calculator is ageless, because its primary 
clinical aim is to detect all individuals at risk of develop-
ing psychosis at scale, in secondary mental health care. 
It can, therefore, be used in the 15–35 age range of peak 
psychosis risk52 as well as outside of this range. This is 
clinically important in the United Kingdom because with 
the recent introduction of new governmental acts,53 early 
intervention services for psychosis have become almost 
ageless.54
There are also some considerations for further 
research. This is the first transdiagnostic risk calcula-
tor available. Although the transdiagnostic approach is 
becoming popular, its exact meaning remains somewhat 
obscure. From the Latin etymology, the prefix “trans-” 
could mean either “across” or “beyond” (Oxford diction-
ary https://en.oxforddictionaries.com/definition/trans-). 
We here replicate—for the second time—the clinical reli-
ability and usefulness of psychiatrists’ classification of 
broad diagnostic phenomenological spectra (the ICD-
10 diagnoses were indeed pooled into larger diagnostic 
clusters as indicated in supplementary eTable 2) to build 
clinical prediction models. At a time of likely excessive 
claims and enthusiasm to abandon and go “beyond” psy-
chiatric diagnoses, in the real world of busy NHS Trusts, 
classification of patients’ problems has yet to be replaced 
by anything better and is still entirely based on psycho-
pathology.55 Our evidence-based pragmatic approach51 
follows an incremental improvement of knowledge 
framework—which has worked in the rest of medicine—
and thus rather than moving “beyond” broad diagnostic 
spectra, it works “across” them. Moreover, to be prag-
matically useful, prognostic risk models must show above 
chance performance (ie, greater than 0.5), and if  imple-
mented on a large scale, even risk prediction models with 
a modest accuracy (of about 0.65) may be considered 
of clinical utility.56 Furthermore, the current model is 
based on a few predictors, and as such, it could represent 
a benchmark for future refinements. For example, neu-
robiological biomarkers that are currently under investi-
gation hold potential promise for improving specificity.57 
However, as more factors are included, the risk algorithm 
becomes more complex, time consuming, and costly. This 
increase in model complexity can impact the usage of the 
risk prediction tool in the broader clinical scenario.49 For 
a risk calculator to be pragmatically used in front-line 
clinical settings with the primary aim of improving the 
detection of individuals at risk of psychosis, sophisticated 
and cost-intensive neuroimaging or peripheral measures 
are unlikely to be a viable solution. Instead, our calcula-
tor could be used to primarily detect at-risk individuals 
as soon as they contact NHS secondary mental health 
services, as a first step. In the second step, those who are 
detected could undergo a proper CHR-P assessment. In 
a further step, those testing positive at the CHR-P inter-
view could then be subjected to biomarker-based risk 
stratification models. In a recent meta-analytical simula-
tion, we confirmed that such a sequential combination of 
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clinical, electrophysiological, neuroimaging, and periph-
eral risk stratification models in CHR-P samples could 
potentially increase the prognostic accuracy.58 The gen-
eral concept of sequential testing is in line with the clini-
cal staging model of early psychosis7 and is an approach 
widely deployed in clinical medicine.
Limitations of this study are mostly inherited from the 
original model and are fully detailed in the supplementary 
eLimitations section. In brief, our diagnoses have high eco-
logical but unclear psychometric validity, the research team 
carrying out this replication study is not completely inde-
pendent from the original one59, it is possible that the model 
is charting out relationships that reflect diagnostic practice 
within the United Kingdom and randomized clinical tri-
als or economic modeling are needed to assess whether our 
risk calculator effectively improves patient outcomes.
Conclusions
The transdiagnostic risk calculator shows an acceptable 
performance even in NHS Trusts in the United Kingdom 
with different sociodemographic characteristics and service 
configurations. This calculator may support an improved 
detection of at-risk cases in secondary mental health care, 
as well as the transdiagnostic prediction of psychosis even 
in NHS Trust that do not provide CHR-P services.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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